.
INTRODUCTION:This study aims to identify the effectiveness of asthma self-management interventions for school-aged children 6-17 years old in the US. The research questions include: (1) What interventions are conducted for asthma self-management among school children and adolescents aged 6-17 with asthma from minority families in the US? (2) Which asthma self-management intervention(s) are effective and feasible to reduce acute healthcare utilisation and improve asthma control among school-aged children 6-17 years and (3) Are there any differences in the effectiveness of self-management interventions by age groups (children 6-11 years vs adolescents 12-17 years) and by income groups (low income vs high income minority families)? METHODS AND ANALYSIS:A thorough search of the literature is conducted in multiple electronic databases, such as MEDLINE, PubMed, Scopus/Embase, EbscoHost, CINAHL-full text, PsycINFO and clinical trials. This review focuses on studies of school-aged children and adolescents 6-17 years old with asthma from minority families that employ self-management intervention to enhance asthma control compared with a standard intervention/control group. The search strategies are developed following the population, intervention, comparison and outcome framework. The primary outcomes of this study are healthcare utilisation (ie, asthma-related urgent care/emergency department visits and hospitalisation), symptom control and asthma control. The process involves developing a search strategy along with inclusion and exclusion criteria, extracting relevant data, assessing the risk of bias (RoB) and analysing the data. The preferred reporting items for systematic reviews and meta-analyses guidelines will be used for reporting of the systematic review. The Cochrane Risk of Bias revised tool will be used to assess the RoB. The findings will be presented descriptively using tables, visual aids and a narrative summary. A meta-analysis will synthesise the results, exploring the impact of various interventions on asthma self-management in low-income and minority adolescents. ETHICS AND DISSEMINATION:Ethical approval is not required for this study since this is a systematic review of existing literature. This study will synthesise evidence of asthma self-management interventions among school-aged children with asthma from minority and low-income families and identify research gaps. The findings in the meta-analysis will offer valuable insights into designing tailored evidence-based, effective, self-management interventions for school-aged children and adolescents with asthma in the future. The findings will be disseminated via peer-reviewed publications and presentations. PROSPERO REGISTRATION NUMBER:CRD42024567466.
OBJECTIVE:Compared with first-generation antihistamines (FGAs), second-generation antihistamines (SGAs) are equally effective, longer acting, and better tolerated. We aimed to reduce the proportion of patients receiving FGAs among all receiving antihistamines from baselines of 74% in the pediatric emergency department (PED) and 54% in inpatient units by 50% within 6 months and sustain this change for 6 months. METHODS:This multidisciplinary quality improvement initiative was conducted between 2022-2024. Implemented interventions were clinician education, flyers, ensuring cetirizine availability, and clinical pathways updates. The outcome measures were the proportion of patients receiving FGAs (diphenhydramine or hydroxyzine) or SGAs (cetirizine) among all receiving antihistamines. The process measures were educational sessions, knowledge assessments, and clinical pathways usage. The balancing measures were emergency department revisit within 48 hours, median inpatient length of stay, and antihistamine cost. We assessed improvement using statistical process control charts. RESULTS:The proportion of patients receiving FGAs decreased from 74% to 28% in the PED and from 54% to 36% in inpatient units. Reductions were sustained for 8.5 and 9 months, respectively. Cetirizine use increased from 31% to 75% in the PED and from 54% to 74% in inpatient units. Knowledge scores doubled posteducation. Clinical pathways usage increased from 36 to 44 clinicians monthly. Emergency department revisits and length of stay remained stable. Monthly median antihistamine costs increased in the PED from $53 to $177 and inpatient from $57 to $104. CONCLUSIONS:Using the Model for Improvement, we reduced FGA use and increased cetirizine use in the PED and inpatient setting.
Objective Lynch syndrome (LS) is a common hereditary cancer predisposition syndrome. This study explores how individuals learning about LS-related cancer risk through a population genomic screening program appraise, reappraise, and manage uncertainty and engage in medical management. Methods We recruited participants with an LS result from a population genomic screening study, purposively sampling based on the characteristics of sex, age, LS gene, and family history of cancer. Semi-structured interviews and chart reviews focused on participants’ experiences of learning about the LS result and making management decisions. Thematic analysis and heatmapping were used to explore participant characteristics related to uncertainty management and clinical engagement. Results Seventeen participants completed interviews, describing uncertainty discrepancies or ambivalent appraisals. Most participants who appraised their LS risk as a threat had high clinical engagement. All participants who had lower clinical engagement received misinformation, had little support from clinicians, or had misunderstandings about LS. Conclusion Accurate information from trusted sources is critical to support uncertainty management and subsequent engagement in clinical risk management choices. Practice Implications Ensuring primary care providers have the information and tools to provide patients with accurate information may support recommended clinical engagement, thereby improving health outcomes for this population.
BACKGROUND:As the pharmacists' role as part of cystic fibrosis (CF) care teams has expanded over the years and recently been redefined as "core" members, their effective electronic medical record (EMR) documentation contributes to clear and effective communication and continuity of care. OBJECTIVES:This study aimed to evaluate current documentation practices and identify possible best practices and opportunities for standardization of pharmacists' documentation during CF clinic visits across centers. METHODS:An electronic, deidentified survey was distributed to pharmacists via the CF Foundation listserv from January 10, 2023 to January 27, 2023. Survey items included multiple-choice questions and an option to upload pharmacist note templates. Two investigators reviewed the templates for common components, reconciling discrepancies with a third reviewer. Components of interest included recommendations, drug interactions, therapy monitoring, adherence assessment, substance screening, medication access and storage, guideline adherence, vaccination recommendations, CF transmembrane conductance regulator modulator eligibility/monitoring, exacerbation history, treatment plan coproduction, transitions of care, and education. Descriptive analysis used Stata SE 16.0. RESULTS:Sixty pharmacists responded, with 94% practicing in the United States. Participants had varied CF care experience (1-10 years: 72.5%) and served pediatric (49%), adult (26.4%), and combined centers (24.5%). Most (84.6%) participated in joint provider visits, frequently in person or virtually (64%). Twenty-four EMR templates were collected, showing varied structures. Common elements were medication adherence and laboratory test results; less consistently included were drug interactions and coproduced goals. CONCLUSION:Pharmacist EMR documentation at CF centers is highly variable. Defining best practices and incorporating coproduction of care could enhance clarity and continuity.